Loading
SMAD7 (SMAD family member 7) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.
Antagonist of signalling by TGF-beta (transforming growth factor) type 1 receptor superfamily members; has been shown to inhibit TGF-beta (Transforming growth factor) and activin signalling by associating with their receptors thus preventing SMAD2 access. Functions as an adapter to recruit SMURF2 to the TGF-beta receptor complex. Also acts by recruiting the PPP1R15A-PP1 complex to TGFBR1, which promotes its dephosphorylation.
Open Targets scores its association with cancer at 0.60 (direct and indirect evidence; datatypes literature 0.99, animal model 0.41, genetic association 0.77).
In plain words · SMAD7 (SMAD family member 7) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.
SMAD7 (SMAD family member 7) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.
Antagonist of signalling by TGF-beta (transforming growth factor) type 1 receptor superfamily members; has been shown to inhibit TGF-beta (Transforming growth factor) and activin signalling by associating with their receptors thus preventing SMAD2 access.
No product in this corpus aims at SMAD7 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
First described 1997. Earliest sequence paper UniProt cites for the protein: Hayashi et al, Cell, 1997, "The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling". Source.
Sources: HGNC HGNC:6773 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O15105 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000101665 (association with cancer (MONDO_0004992) 0.60; per-cancer scores at or above 0.5: colorectal cancer 0.58 (GraphQL API, CC0))
Antagonist of signalling by TGF-beta (transforming growth factor) type 1 receptor superfamily members; has been shown to inhibit TGF-beta (Transforming growth factor) and activin signalling by associating with their receptors thus preventing SMAD2 access. Functions as an adapter to recruit SMURF2 to the TGF-beta receptor complex. Also acts by recruiting the PPP1R15A-PP1 complex to TGFBR1, which promotes its dephosphorylation. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator. Location: Nucleus; Cytoplasm (UniProt). Locus 18q21.1 (HGNC).
Query for this target: (TITLE:"SMAD7" OR ABSTRACT:"SMAD7" OR TITLE:"SMAD family member 7" OR ABSTRACT:"SMAD family member 7" OR TITLE:"MADH8" OR ABSTRACT:"MADH8" OR TITLE:"MADH7" OR ABSTRACT:"MADH7") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SMAD7, not a curated reading list.